SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum
GLD 399.29+0.9%Dec 17 4:00 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: TobagoJack who wrote (174645)7/12/2021 9:18:26 AM
From: marcher1 Recommendation

Recommended By
sense

  Read Replies (1) of 218554
 
jnj fixed it:

"...July 1, 2021 Johnson & Johnson (NYSE: JNJ) (the Company) today announced data that demonstrated
its single-shot COVID-19 vaccine generated strong, persistent activity against the rapidly spreading Delta
variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability
of the immune response lasted through at least eight months, the length of time evaluated to date. The two
preprint study summaries have been submitted today to bioRxiv.

“Today’s newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to
helpprotect the health of people globally,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee
and Chief Scientific Officer at Johnson & Johnson. “We believe that our vaccine offers durable protection
against COVID-19 and elicits neutralizing activity against the Delta variant. This adds to the robust body of
clinical data supporting our single-shot vaccine’s ability to protect against multiple variants of concern.”

jnj.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext